Moleculin to Present Annamycin Cardiac Safety Data at 2026 ASCO Poster Session
Moleculin Biotech’s abstract on annamycin cardiac safety in patients with high cumulative anthracycline exposure has been accepted for the 2026 ASCO Annual Meeting poster session. The pooled analysis evaluates annamycin’s cardiac safety profile against known anthracycline cardiotoxicity, supporting its differentiation in AML and soft tissue sarcoma lung metastases development.
1. ASCO Poster Acceptance
Moleculin Biotech secured acceptance of its abstract titled “Cardiac safety of L-annamycin at high cumulative anthracycline exposure: Pooled analysis” for presentation in the Symptom Science and Palliative Care poster session at the ASCO Annual Meeting. The session is scheduled for May 30, 2026, from 1:30 PM to 4:30 PM CDT at Poster Board #8 in Chicago.
2. Pooled Cardiac Safety Analysis
The abstract details a pooled analysis assessing cardiac safety outcomes for patients receiving annamycin after substantial anthracycline exposure. This analysis addresses cardiotoxicity concerns common to the anthracycline class and highlights annamycin’s tolerability at elevated cumulative doses.
3. Development Context
These cardiac safety findings reinforce annamycin’s potential as a differentiated anthracycline and may de-risk its Phase 3 MIRACLE trial in relapsed or refractory acute myeloid leukemia. Positive safety data could also bolster development for treatment of soft tissue sarcoma lung metastases.